Osaka University Venture Capital

Ayumo is a research and development company that provides deep learning services with medical insights and AI technology.

RegCell is focused on developing innovative therapies for autoimmune diseases and cancer by enhancing or regulating the immune system. The company specializes in creating cell therapies that aim to address significant unmet medical needs. By returning regulatory T cells to the patient and activating them in vitro, RegCell seeks to provide effective treatment options for individuals suffering from these challenging conditions. Through its novel approach, the company aims to improve patient outcomes and address the complexities associated with autoimmune disorders and cancer.

QunaSys is a developer of software focused on algorithm and application development to advance the practical use of quantum technology. The company aims to harness quantum properties to create technologies that traditional methods cannot achieve. Its platform simulates phenomena related to the quantum mechanical behavior of electrons and atomic nuclei, facilitating the execution of quantum chemistry calculation algorithms on both quantum computers and simulators. By bridging the gap between theoretical quantum physics and practical applications, QunaSys seeks to bring quantum technologies to the forefront, enabling researchers to effectively explore and utilize these advanced capabilities.

A-Wave is a manufacturing company that develops and markets medical devices, pharmaceuticals, computer software, and hardware.

Alpha Fusion specializes in the development of astatine-based radiopharmaceuticals for targeted alpha therapy, focusing on innovative cancer treatment solutions. The company is engaged in drug discovery and business development of low-molecular-weight and antibody-introduced astatine compounds. By harnessing alpha-ray nuclear medicine therapy, Alpha Fusion aims to provide healthcare providers with effective tools to combat cancer, enhancing treatment options for patients.

Luxna Biotech Co., Ltd. is a Japanese company focused on the development of nucleic acid drugs, utilizing advanced technology to enhance the practical application of these therapies. Founded in 2017 and based in Suita, Japan, the company provides drug discovery support through artificial nucleic acid technology. Luxna Biotech aims to contribute to medical treatment, addressing the needs of patients with various health conditions.

Celaid Therapeutics focuses on the development and commercialization of regenerative medicine products that utilize human hematopoietic stem cells. The company specializes in cell therapy, leveraging advanced techniques for the expansion of these stem cells to create innovative medical solutions. In addition to its therapeutic offerings, Celaid Therapeutics also supports research and discovery by providing essential media reagents. This approach enables medical professionals to enhance hematopoietic stem cell transplantation and integrate gene-editing technology into their treatments, thereby advancing the field of regenerative medicine.

Developer of a healthcare technology designed to replace the traditional way of treating cancer treatment. The company aims to transform the traditional therapeutic into a next-generation therapy for cancer diseases by maximizing the drug potency with minimum toxicity, helping the healthcare sector to overcome systemic toxicity and exhibiting strong anti-tumor efficacy in various tumor models both as monotherapy and in combination with immune checkpoint inhibitors.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy, utilizing advanced technology to create therapeutic agents that address intractable eye conditions. Restore Vision's approach involves the use of chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins, allowing for increased sensitivity in patients. This technology aims to improve treatment outcomes for individuals suffering from various eye disorders, providing new hope for visual restoration.

Thinker provides sales of proximity sensors and proposed solutions using these products.

EX-Fusion is focused on developing and operating the world's first laser-powered commercial nuclear fusion reactor, aiming to provide sustainable energy solutions. The company specializes in manufacturing continuous plasma generators and offers technology for fusion systems, alongside conducting laser-plasma research. This initiative addresses the limitations of traditional government-funded fusion research, which often faces delays due to political and budgetary constraints. By pursuing an independent approach to fusion technology, EX-Fusion seeks to advance the practical application of laser fusion reactors, potentially revolutionizing the energy sector.

GAIA BioMedicine Inc. is a biopharmaceutical company based in Fukuoka Prefecture, Japan, founded in 2015 as a spin-off from Kyushu University. The company focuses on developing regenerative medicine products, specifically specializing in cell treatments and immunotherapies aimed at combating intractable malignancies. GAIA BioMedicine employs advanced technology to harness the power of genes and the immune system, enabling patients to better fight challenging diseases. With a commitment to innovation, the firm seeks to address significant unmet medical needs in cancer treatment through its specialized therapies.

GAIA BioMedicine Inc. is a biopharmaceutical company based in Fukuoka Prefecture, Japan, founded in 2015 as a spin-off from Kyushu University. The company focuses on developing regenerative medicine products, specifically specializing in cell treatments and immunotherapies aimed at combating intractable malignancies. GAIA BioMedicine employs advanced technology to harness the power of genes and the immune system, enabling patients to better fight challenging diseases. With a commitment to innovation, the firm seeks to address significant unmet medical needs in cancer treatment through its specialized therapies.

SK Fine is a pioneer in the field of 3D printing technology, being the first company in Japan to develop and market a 3D printer specifically for ceramics. The company specializes in producing ceramic parts that cannot be manufactured using traditional methods. By leveraging three-dimensional CAD data provided by clients, SK Fine creates customized ceramic components tailored to specific requirements. Additionally, the firm is advancing the development of 3D printing processes for various ceramic applications, allowing for greater flexibility and innovation in the production of ceramic parts. This focus on customization and technological advancement positions SK Fine as a leader in the ceramic 3D printing industry.

JiMED is a company specializing in wireless embedded brain-computer interface (BCI) systems that monitor brain activity. It offers a wireless implantable BCI system that utilizes an implanted device in conjunction with artificial intelligence to interpret brain signals. This innovative technology allows individuals with ALS to control the device through thought, significantly enhancing their ability to communicate and improve their quality of life.

Immunosens is a developer of electrochemical measurement devices that evaluate biomarkers, including genes, proteins, and cell signals, through electrode reactions. The company focuses on creating products that utilize disposable printable electrodes in their sensors, which enhances the accuracy of analyses and measurements. This technology is particularly beneficial for healthcare professionals in diagnosing medical conditions and conducting food safety inspections, ensuring reliable results in both domains.

HULIX Technologies specializes in developing and selling platforms for human flow space analysis. The company offers several services, including Human Navigation Research, which automatically gathers and visualizes human behavior data to identify unseen issues. Additionally, HULIX provides Hitonavi Cloud Basic, designed for conducting people flow surveys and verifications, and Hitonavi Cloud Advanced, which leverages collected data for applications in marketing, smart cities, security, and energy management. HULIX also focuses on creating a digital twin platform that enhances understanding of the real world for both humans and machines, promoting advancements in smart societal and industrial solutions while fostering a human-centered environment.

Aipore Inc. is a technology company based in Shibuya-ku, Tokyo, Japan, specializing in the development of nanopore sensors that leverage semiconductor microfabrication technology. Founded in 2018, the company focuses on creating IoT-based sensors capable of measuring and analyzing changes in ion current to identify fine particles, including nanoparticles and viruses, with high accuracy. Aipore's innovative technology integrates various advancements such as silicon MEMS, flow path surface control, and low noise amplification circuits, along with artificial intelligence to enhance the analysis of transient ion current changes. These sensors have diverse industrial applications, including microorganism identification, laboratory testing, cancer detection, blood diagnostics, livestock inspection, and environmental evaluations, enabling precise measurement of microparticles across different sectors.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

Periotherapia is a drug discovery company focused on developing targeted medical treatments for intractable diseases, with a particular emphasis on triple negative breast cancer as its primary indication. The company aims to selectively inhibit specific disease-related pathways, notably the ASV involved in disease pathogenesis, while preserving the physiological functions of ASV in chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine through companion diagnostics, thereby enhancing the ability of healthcare professionals to discover new therapeutic options for these challenging diseases.

GlyTech, Inc. specializes in the production of human-type N-glycans and the development of glycosylation technologies, including glycopeptide and glycoprotein synthesis. Founded in 2012 and based in Kyoto, Japan, the company focuses on enhancing the development of biopharmaceuticals and oligonucleotide therapeutics through innovative glycan production techniques. GlyTech offers a range of services, including custom synthesis, contract research and development, and the licensing of glycosylated peptides and proteins. Additionally, the company supplies standard reagents, supporting researchers in their efforts to advance human health by expanding their capabilities in glycoscience research and biotherapeutic analysis.

J-Pharma is a pharmaceutical company focused on developing novel drugs through a human-genomic approach, specifically targeting cell membrane transporters associated with various diseases. The company aims to create selective agents for treating conditions such as cancer by developing anti-cancer drugs and PET diagnostic agents that interact with transporters like LAT1, which are linked to cancer cell growth. J-Pharma's research emphasizes the importance of understanding drug transporters to enhance the pharmacokinetics of new drug candidates. By discovering key transporters within the human body, J-Pharma seeks to advance diagnostic methods and improve treatment options, thereby contributing to global health and enhancing the quality of life for aging populations in industrialized countries.

PGV Co., Ltd., established in September 2016 and headquartered in Japan, focuses on the development of advanced electroencephalograph (EEG) technology. The company specializes in creating a brain wave sensor device that allows for accurate measurement of brain waves, facilitating self-care and understanding of individual brain activity throughout various life stages. PGV aims to simplify EEG monitoring through its innovative patch-type electroencephalographs, making the process as straightforward as using a thermometer. By leveraging artificial intelligence for data analysis, PGV's technology supports both medical professionals in providing efficient patient care and individuals in managing their own brain health.

ThinkCyte, Inc. is a biotechnology company based in Tokyo, Japan, with an additional office in San Carlos, California. Founded in 2016, it specializes in developing an innovative cell sorting technology known as ghost cytometry, which leverages advanced optics and machine learning to perform high-throughput, image-free analysis and sorting of cells based on their morphology. This technology is designed for various applications in research, diagnostics, and therapeutics, facilitating single-cell analysis that is crucial for drug discovery, cell therapy, and clinical diagnostics. By enabling researchers to identify and isolate target cells, including rare cells, in real time, ThinkCyte aims to enhance the efficiency and accuracy of biological research and medical applications.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company focuses on the research and development of hepatocyte growth factor (HGF) and its applications in treating various medical conditions. Kringle Pharma's HGF products aim to promote regenerative healing in liver cells and other organs, addressing acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scars. Additionally, the company develops NK4, a bi-functional molecule that serves as an HGF antagonist, inhibiting tumor cell invasion and metastasis while exhibiting antiangiogenic properties. Kringle Pharma's pipeline includes recombinant human HGF for acute renal failure and skin ulcers, as well as NK4-based therapies for cancer treatment.

Luxna Biotech Co., Ltd. is a Japanese company focused on the development of nucleic acid drugs, utilizing advanced technology to enhance the practical application of these therapies. Founded in 2017 and based in Suita, Japan, the company provides drug discovery support through artificial nucleic acid technology. Luxna Biotech aims to contribute to medical treatment, addressing the needs of patients with various health conditions.

PGV Co., Ltd., established in September 2016 and headquartered in Japan, focuses on the development of advanced electroencephalograph (EEG) technology. The company specializes in creating a brain wave sensor device that allows for accurate measurement of brain waves, facilitating self-care and understanding of individual brain activity throughout various life stages. PGV aims to simplify EEG monitoring through its innovative patch-type electroencephalographs, making the process as straightforward as using a thermometer. By leveraging artificial intelligence for data analysis, PGV's technology supports both medical professionals in providing efficient patient care and individuals in managing their own brain health.

Remohab Corporation, founded in 2017 and based in Suita City, Japan, specializes in remote telemedicine focused on rehabilitation, particularly for cardiac patients. The company has developed a system that utilizes ICT and IoT technologies to facilitate at-home cardiac rehabilitation. This innovative approach connects patients with healthcare professionals in remote medical institutions, allowing for continuous monitoring and support. The system provides a range of activity programs that patients can perform at home, enabling them to manage their health effectively while receiving guidance from nurses and healthcare providers.

mediVR, Inc. specializes in the development and sale of therapeutic medical devices that utilize virtual reality, three-dimensional tracking, and artificial intelligence to assist in exercise rehabilitation. The company's flagship product, mediVR Kagura, is a self-exercise device designed to assess motor function, posture balance, and cognitive abilities necessary for walking. By employing engaging activities and games, the device aims to enhance rehabilitation for patients, particularly those recovering from strokes. MediVR markets its products through a network of distributors and operates from its headquarters in Tokyo, Japan, with an additional office in Osaka. Founded in 2016, the company is focused on improving healthcare systems through innovative technology.

Immunosens is a developer of electrochemical measurement devices that evaluate biomarkers, including genes, proteins, and cell signals, through electrode reactions. The company focuses on creating products that utilize disposable printable electrodes in their sensors, which enhances the accuracy of analyses and measurements. This technology is particularly beneficial for healthcare professionals in diagnosing medical conditions and conducting food safety inspections, ensuring reliable results in both domains.

Cykinso, Inc. is a Japan-based company established in 2014 that specializes in direct-to-consumer microbiome testing kits. The company offers a home-testing kit designed to assess the state of an individual's intestinal bacteria. Utilizing advanced sequencing technology, the kit analyzes numerous DNA sequences rapidly, providing users with insights into their gut health. This information helps individuals understand the relationship between their intestinal flora and various lifestyle-related and digestive diseases. Through its innovative testing service, Cykinso aims to empower consumers with knowledge about their health conditions based on detailed bacterial flora data.

MiCAN Technologies Inc. specializes in producing and supplying blood cell-like products for research purposes, utilizing advanced regenerative medicine technology. Founded in 2016 and based in Kyoto, Japan, the company focuses on developing new drugs for infectious diseases such as malaria and dengue. MiCAN offers specific products like MPV, a red blood-like cell designed for malaria research, and M02, a myeloid lineage cell suitable for dengue research. By providing homogeneous and stable experimental cells, MiCAN Technologies aims to streamline drug evaluation processes, enabling researchers and developers to discover new treatments for these diseases more efficiently and cost-effectively.

AI Samurai Inc. is a company based in Tokyo, Japan, with a branch office in Osaka, specializing in the development and sales of artificial intelligence technology. Founded in 2015, the company focuses on creating a patent examination platform that leverages AI to evaluate patentability and conduct comprehensive patent searches. This platform aids clients in their research and development efforts by enabling detailed analyses of all patent documents within its database. In addition to its core offerings, AI Samurai also supports patent research and technical investigations, positioning itself as a valuable resource in the field of intellectual property.

Telenoid Healthcare Company Ltd., founded in 2015 and based in Tokyo, Japan, focuses on developing innovative solutions for elderly individuals with dementia. The company's flagship product, the Terenoid app, facilitates communication between dementia patients and their caregivers through a device equipped with a camera and microphone, allowing remote interaction. In addition to the Terenoid app, Telenoid offers the Chatter Box service, which provides a consulting platform for nursing care leaders, integrating a knowledge database that supports communication and enhances staff training. This service helps junior caregivers understand the perspectives of their senior counterparts by compiling personality data and insights from experienced staff. Telenoid's commitment to improving care for the elderly is reflected in its multi-disciplinary approach, which includes applications for research and educational institutions.

Periotherapia is a drug discovery company focused on developing targeted medical treatments for intractable diseases, with a particular emphasis on triple negative breast cancer as its primary indication. The company aims to selectively inhibit specific disease-related pathways, notably the ASV involved in disease pathogenesis, while preserving the physiological functions of ASV in chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine through companion diagnostics, thereby enhancing the ability of healthcare professionals to discover new therapeutic options for these challenging diseases.

PaMeLa Co., Ltd. is a medical device company based in Suita, Japan, founded in 2016. The company focuses on developing innovative technology to measure pain experienced by patients during surgical procedures. By utilizing brain wave analysis, algorithms, and machine learning, PaMeLa aims to create an objective method for quantifying pain. This approach is intended to enhance medical care by providing a scientific basis for pain assessment, thereby improving patient outcomes and treatment strategies.

ThinkCyte, Inc. is a biotechnology company based in Tokyo, Japan, with an additional office in San Carlos, California. Founded in 2016, it specializes in developing an innovative cell sorting technology known as ghost cytometry, which leverages advanced optics and machine learning to perform high-throughput, image-free analysis and sorting of cells based on their morphology. This technology is designed for various applications in research, diagnostics, and therapeutics, facilitating single-cell analysis that is crucial for drug discovery, cell therapy, and clinical diagnostics. By enabling researchers to identify and isolate target cells, including rare cells, in real time, ThinkCyte aims to enhance the efficiency and accuracy of biological research and medical applications.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, founded in 2018. The company specializes in the research and development of genome editing technologies, particularly utilizing CRISPR and Cas3 methods. C4U aims to support drug discovery and develop new gene therapies for various intractable diseases. By applying its innovative technologies across multiple sectors, including medical, agricultural, forestry, livestock, and fishery, C4U seeks to address significant social issues.

SK Fine is a pioneer in the field of 3D printing technology, being the first company in Japan to develop and market a 3D printer specifically for ceramics. The company specializes in producing ceramic parts that cannot be manufactured using traditional methods. By leveraging three-dimensional CAD data provided by clients, SK Fine creates customized ceramic components tailored to specific requirements. Additionally, the firm is advancing the development of 3D printing processes for various ceramic applications, allowing for greater flexibility and innovation in the production of ceramic parts. This focus on customization and technological advancement positions SK Fine as a leader in the ceramic 3D printing industry.

Aipore Inc. is a technology company based in Shibuya-ku, Tokyo, Japan, specializing in the development of nanopore sensors that leverage semiconductor microfabrication technology. Founded in 2018, the company focuses on creating IoT-based sensors capable of measuring and analyzing changes in ion current to identify fine particles, including nanoparticles and viruses, with high accuracy. Aipore's innovative technology integrates various advancements such as silicon MEMS, flow path surface control, and low noise amplification circuits, along with artificial intelligence to enhance the analysis of transient ion current changes. These sensors have diverse industrial applications, including microorganism identification, laboratory testing, cancer detection, blood diagnostics, livestock inspection, and environmental evaluations, enabling precise measurement of microparticles across different sectors.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

AI Samurai Inc. is a company based in Tokyo, Japan, with a branch office in Osaka, specializing in the development and sales of artificial intelligence technology. Founded in 2015, the company focuses on creating a patent examination platform that leverages AI to evaluate patentability and conduct comprehensive patent searches. This platform aids clients in their research and development efforts by enabling detailed analyses of all patent documents within its database. In addition to its core offerings, AI Samurai also supports patent research and technical investigations, positioning itself as a valuable resource in the field of intellectual property.

NanoMist Technologies engages with R&D, design, and sells machines in the areas such as alcoholic beverages and food enrichment, fragrance extraction, chemical purification process, wastewater management, and deodorization process. NanoMist Technologies manufactures and sells machines such as ultrasonic atomization machine, deodorization machine, hot spring water concentration machine, solvent recovery machine, VOCs recovery machine, and granular material production machine.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, founded in 2018. The company specializes in the research and development of genome editing technologies, particularly utilizing CRISPR and Cas3 methods. C4U aims to support drug discovery and develop new gene therapies for various intractable diseases. By applying its innovative technologies across multiple sectors, including medical, agricultural, forestry, livestock, and fishery, C4U seeks to address significant social issues.

MediTact is Contribute to the medical society through the challenging development of medical technologies that meet patient treatment needs.

ThinkCyte, Inc. is a biotechnology company based in Tokyo, Japan, with an additional office in San Carlos, California. Founded in 2016, it specializes in developing an innovative cell sorting technology known as ghost cytometry, which leverages advanced optics and machine learning to perform high-throughput, image-free analysis and sorting of cells based on their morphology. This technology is designed for various applications in research, diagnostics, and therapeutics, facilitating single-cell analysis that is crucial for drug discovery, cell therapy, and clinical diagnostics. By enabling researchers to identify and isolate target cells, including rare cells, in real time, ThinkCyte aims to enhance the efficiency and accuracy of biological research and medical applications.

Chromocenter Inc. is a biotechnology company based in Yonago, Japan, founded in 2005. The company specializes in developing artificial chromosome technologies primarily for applications in the life sciences and biopharmaceutical industries. Its innovations include the use of artificial chromosome vectors for drug discovery and the creation of stable gene expression cell lines, which facilitate high protein production. Chromocenter also engages in the production of transgenic animals and offers various chromosome analysis services, including multicolor FISH and mapping FISH. The organization's goal is to enhance the development of safe and effective medical pharmaceuticals, ultimately contributing to the treatment of various diseases.

Chromocenter Inc. is a biotechnology company based in Yonago, Japan, founded in 2005. The company specializes in developing artificial chromosome technologies primarily for applications in the life sciences and biopharmaceutical industries. Its innovations include the use of artificial chromosome vectors for drug discovery and the creation of stable gene expression cell lines, which facilitate high protein production. Chromocenter also engages in the production of transgenic animals and offers various chromosome analysis services, including multicolor FISH and mapping FISH. The organization's goal is to enhance the development of safe and effective medical pharmaceuticals, ultimately contributing to the treatment of various diseases.

Jeplan, Inc. is a Japanese company specializing in recycling technologies and systems aimed at promoting sustainable practices. Founded in January 2007 and based in Tokyo, it develops innovative solutions that cater to diverse consumer needs. The company utilizes proprietary chemical recycling technology to transform waste materials, such as food packaging and plastic PET bottles, into recycled polyethylene terephthalate (r-PET) resin and Bis(2-Hydroxyethyl) terephthalate (r-BHET) resin. These recycled materials are then used in the manufacturing of various products, including PET bottles and textiles. In addition to its technological advancements, Jeplan is involved in promoting the recycling of used uniforms and offers consulting services to businesses looking to implement recycling initiatives. Through its efforts, Jeplan aims to enhance recycling efficiency and contribute to environmental sustainability.

GlyTech, Inc. specializes in the production of human-type N-glycans and the development of glycosylation technologies, including glycopeptide and glycoprotein synthesis. Founded in 2012 and based in Kyoto, Japan, the company focuses on enhancing the development of biopharmaceuticals and oligonucleotide therapeutics through innovative glycan production techniques. GlyTech offers a range of services, including custom synthesis, contract research and development, and the licensing of glycosylated peptides and proteins. Additionally, the company supplies standard reagents, supporting researchers in their efforts to advance human health by expanding their capabilities in glycoscience research and biotherapeutic analysis.

Immunosens is a developer of electrochemical measurement devices that evaluate biomarkers, including genes, proteins, and cell signals, through electrode reactions. The company focuses on creating products that utilize disposable printable electrodes in their sensors, which enhances the accuracy of analyses and measurements. This technology is particularly beneficial for healthcare professionals in diagnosing medical conditions and conducting food safety inspections, ensuring reliable results in both domains.

Luxna Biotech Co., Ltd. is a Japanese company focused on the development of nucleic acid drugs, utilizing advanced technology to enhance the practical application of these therapies. Founded in 2017 and based in Suita, Japan, the company provides drug discovery support through artificial nucleic acid technology. Luxna Biotech aims to contribute to medical treatment, addressing the needs of patients with various health conditions.

Pi-Crystal Incorporation, founded in 2013 and based in Osaka, Japan, specializes in the development and manufacturing of printable organic semiconductor integrated circuits. The company focuses on research, design, and sales of organic semiconductor materials and devices, as well as offering consulting services in organic semiconductor technology. Pi-Crystal’s innovative products are tailored for a wide range of industrial applications, utilizing unique materials and film formation methods distinct from traditional silicon semiconductors. This approach allows clients to produce flexible, lightweight, and cost-effective devices, thereby advancing technologies within the Internet of Things sector.

Periotherapia is a drug discovery company focused on developing targeted medical treatments for intractable diseases, with a particular emphasis on triple negative breast cancer as its primary indication. The company aims to selectively inhibit specific disease-related pathways, notably the ASV involved in disease pathogenesis, while preserving the physiological functions of ASV in chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine through companion diagnostics, thereby enhancing the ability of healthcare professionals to discover new therapeutic options for these challenging diseases.

Elvez is a company focused on the research, development, and commercialization of dialogue technology. It provides a range of services, including a training management system, a WordPress plugin, and AI-based consulting services. Elvez aims to address social issues through its technology, offering solutions that are accessible via smartphones and web browsers. By leveraging AI technology, the company seeks to enhance the effectiveness of consulting services, particularly for seniors, thereby facilitating better engagement with technology.

PGV Co., Ltd., established in September 2016 and headquartered in Japan, focuses on the development of advanced electroencephalograph (EEG) technology. The company specializes in creating a brain wave sensor device that allows for accurate measurement of brain waves, facilitating self-care and understanding of individual brain activity throughout various life stages. PGV aims to simplify EEG monitoring through its innovative patch-type electroencephalographs, making the process as straightforward as using a thermometer. By leveraging artificial intelligence for data analysis, PGV's technology supports both medical professionals in providing efficient patient care and individuals in managing their own brain health.

Remohab Corporation, founded in 2017 and based in Suita City, Japan, specializes in remote telemedicine focused on rehabilitation, particularly for cardiac patients. The company has developed a system that utilizes ICT and IoT technologies to facilitate at-home cardiac rehabilitation. This innovative approach connects patients with healthcare professionals in remote medical institutions, allowing for continuous monitoring and support. The system provides a range of activity programs that patients can perform at home, enabling them to manage their health effectively while receiving guidance from nurses and healthcare providers.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The platform utilizes advanced algorithms to analyze immune cell sequences and data derived from routine blood samples, providing insights into the structure and function of these receptors with remarkable precision. This technology has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with universities, research institutions, and pharmaceutical companies to enhance the development of diagnostic and treatment methods. Their Repertoire Builder tool organizes receptors based on their target epitopes, employing both sequence and structural characteristics from B and T cell receptor models. This capability reveals the functional landscape of individual donors and quantifies variations among them, thereby facilitating drug discovery and improving diagnostic and prognostic outcomes.

KYSHOW Corporation, founded in 1994 and based in Osaka, Japan, operates seafood retail stores that specialize in high-quality fresh fish. The company focuses on domestically produced live natural fish sourced from Japan's coastal waters, ensuring freshness and quality for its customers. In addition to retailing fresh fish, KYSHOW also manufactures and distributes seasonal gifts, particularly midyear and year-end offerings, in collaboration with renowned department stores. This dual approach enables consumers to access fresh seafood while providing options for gift-giving, catering to both everyday and special occasion needs.

Bioworks Corporation, established in 2015 and headquartered in Tokyo, Japan, specializes in the modification and sale of polylactic acid and its derivatives. The company focuses on enhancing the properties of polylactic acid to create modified compounds that meet various industrial needs. As of December 2018, Bioworks operates as a subsidiary of TBM Co., Ltd. Through its innovative approaches in bioplastics, Bioworks aims to contribute to sustainable material solutions in the production industry.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The platform utilizes advanced algorithms to analyze immune cell sequences and data derived from routine blood samples, providing insights into the structure and function of these receptors with remarkable precision. This technology has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with universities, research institutions, and pharmaceutical companies to enhance the development of diagnostic and treatment methods. Their Repertoire Builder tool organizes receptors based on their target epitopes, employing both sequence and structural characteristics from B and T cell receptor models. This capability reveals the functional landscape of individual donors and quantifies variations among them, thereby facilitating drug discovery and improving diagnostic and prognostic outcomes.

PGV Co., Ltd., established in September 2016 and headquartered in Japan, focuses on the development of advanced electroencephalograph (EEG) technology. The company specializes in creating a brain wave sensor device that allows for accurate measurement of brain waves, facilitating self-care and understanding of individual brain activity throughout various life stages. PGV aims to simplify EEG monitoring through its innovative patch-type electroencephalographs, making the process as straightforward as using a thermometer. By leveraging artificial intelligence for data analysis, PGV's technology supports both medical professionals in providing efficient patient care and individuals in managing their own brain health.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The platform utilizes advanced algorithms to analyze immune cell sequences and data derived from routine blood samples, providing insights into the structure and function of these receptors with remarkable precision. This technology has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with universities, research institutions, and pharmaceutical companies to enhance the development of diagnostic and treatment methods. Their Repertoire Builder tool organizes receptors based on their target epitopes, employing both sequence and structural characteristics from B and T cell receptor models. This capability reveals the functional landscape of individual donors and quantifies variations among them, thereby facilitating drug discovery and improving diagnostic and prognostic outcomes.

Chromocenter Inc. is a biotechnology company based in Yonago, Japan, founded in 2005. The company specializes in developing artificial chromosome technologies primarily for applications in the life sciences and biopharmaceutical industries. Its innovations include the use of artificial chromosome vectors for drug discovery and the creation of stable gene expression cell lines, which facilitate high protein production. Chromocenter also engages in the production of transgenic animals and offers various chromosome analysis services, including multicolor FISH and mapping FISH. The organization's goal is to enhance the development of safe and effective medical pharmaceuticals, ultimately contributing to the treatment of various diseases.

Kyoto Drug Discovery and Development Co. Ltd., based in Kyoto, Japan, specializes in the development of therapeutic drugs aimed at treating chronic degenerative eye diseases. The company focuses on innovative agents for conditions such as glaucoma, central retinal artery occlusion (CRAO), retinitis pigmentosa, and age-related macular degeneration (AMD), which are often considered incurable or intractable. By creating effective treatments for these serious conditions, Kyoto Drug Discovery and Development enables healthcare professionals to better diagnose and manage patients suffering from these debilitating eye diseases.

AFI, established in Seoul, South Korea in 2013, is a technology company focused on food safety and quality. It manufactures and sells innovative products, including an electric filter separation technology and a rapid detection system for microbial contamination, serving the food and life science industries. AFI's solutions enable clients to monitor and enhance food safety, responding to diverse client needs such as rapid microbiological testing.

FunPep is a biotechnology company dedicated to the research and development of pharmaceuticals, cosmetics, and medical devices centered on functional peptides. The company specializes in creating treatments for intractable peptic ulcer disease, including antibody drugs and other pharmaceutical products. FunPep aims to innovate within the pharmaceutical sector by replacing traditional antibody medicines with next-generation products that utilize antibody-inducing peptides. Through its diverse portfolio, FunPep seeks to advance healthcare solutions and improve patient outcomes.

Matrixome Inc, established in 2015 and headquartered in Osaka, Japan, specializes in the research and development of protein-based pharmaceutical products. The company focuses on the concept of 'matrixosome', which emphasizes the crucial role of cell-extracellular environment interactions in determining cell behavior and fate. Matrixome's product portfolio includes iMAtrix-221, iMatrix-441, and iMatrix-511, each designed to support and manipulate specific cell types for research and regenerative medicine applications.

JTEC Corporation, founded in 1993 and headquartered in Ibaraki, Japan, specializes in the design, manufacture, and sale of X-ray mirrors used in synchrotron facilities. These mirrors support research across various fields, including pharmaceuticals, electronics, materials, food, and beauty. In addition to X-ray mirrors, the company develops and produces automated cell culture systems and various automated systems for different applications. Its optical product lineup includes several types of mirrors, such as Kirkpatrick-Baez and deformable mirrors, as well as X-ray focusing alignment systems. JTEC Corporation's commitment to innovation and quality positions it as a key player in the fields of optics and life sciences.

Microwave Chemical is a company focused on the research and development of microwave technology. It specializes in engineering and licensing microwave processes tailored to specific product characteristics. The company offers comprehensive solutions that leverage its microwave platform technology, aiming to enhance efficiency and effectiveness in various applications.